Reta ZPHC (AQ Pen) — 30 mg Premixed Pen

Product Overview

Reta ZPHC (AQ Pen) — 30 mg Premixed Pen is a product marketed under the name retatrutide, an investigational compound currently being studied for its effects on metabolic health and body weight. For U.S. audiences searching for ZPHC, Reta ZPHC is a product name that may appear in online research-chemical and peptide markets.

Retatrutide itself is not an FDA-approved medication as of 2026. It is an investigational triple hormone receptor agonist being developed by Eli Lilly and studied in Phase 3 clinical trials. Lilly describes retatrutide as activating the GIP, GLP-1, and glucagon receptors.

Because regulatory status matters when evaluating any product marketed as retatrutide, consumers should distinguish between an investigational compound used in controlled clinical research and products sold through unofficial or online channels.

What Is Retatrutide?

Retatrutide, also known by its development code LY3437943, is an investigational molecule designed to activate three hormone receptors: GIP, GLP-1, and glucagon. This triple-agonist mechanism is why retatrutide has attracted substantial interest in metabolic-health research.

Clinical research is evaluating retatrutide in adults with obesity, overweight, type 2 diabetes, and obesity-related complications. Lilly’s development program includes studies involving cardiovascular disease, knee osteoarthritis, obstructive sleep apnea, and other metabolic conditions.

This research has generated significant interest because clinical-trial results have reported substantial changes in body weight and measures of glycemic control. However, investigational results should not be interpreted as establishing that an independently marketed product is safe, effective, or equivalent to the material administered in a controlled clinical trial.

Understanding the ZPHC Product Name

The term ZPHC may be used as a brand or manufacturer identifier in product listings. The designation “AQ pen” and the stated 30 mg quantity describe how the particular listing is presented, but those labels alone do not establish regulatory approval, pharmaceutical quality, sterility, identity, potency, or clinical equivalence.

For consumers researching Reta ZPHC, it is important to verify the exact product, manufacturer information, labeling, regulatory status, and applicable legal requirements rather than relying solely on product names or marketing claims.

A product described as “premixed” or supplied in a pen should not automatically be considered equivalent to an FDA-approved prescription medicine. Packaging and delivery format do not independently establish product quality or safety.

Current U.S. Regulatory Status

Retatrutide remains an investigational medication. Lilly’s September 2026 information states that retatrutide has not been approved by the FDA or any other regulatory agency and is currently being evaluated through clinical trials.

The FDA has also taken enforcement action concerning websites marketing unapproved retatrutide products. For example, an FDA warning letter issued in 2026 identified retatrutide products marketed for sale in the United States as unapproved new drugs.

This makes regulatory verification especially important for anyone searching online for terms such as:

• ZPHC
• Reta ZPHC
• Reta ZPHC AQ Pen
• Retatrutide 30 mg
• Retatrutide premixed pen
• Retatrutide USA
• ZPHC retatrutide
• Reta research compound
• Retatrutide clinical research

Search interest does not change the legal or medical status of an investigational compound.

What Clinical Research Has Found

Retatrutide has produced noteworthy findings in clinical development, which helps explain the growing interest surrounding the compound. In a Phase 3 obesity trial, Lilly reported that participants receiving 12 mg retatrutide experienced an average 28.3% reduction in body weight after 80 weeks.

Additional Phase 3 research involving participants with obesity and type 2 diabetes reported average weight reductions of up to 20.8% at 80 weeks at the 12 mg dose, alongside improvements in A1C.

These findings are scientifically significant, but they should be understood in context. Clinical-trial results apply to the specific investigational product, study design, population, dosing protocol, monitoring, and conditions under which the research was conducted. They should not be used to establish the safety or effectiveness of an independently marketed Reta ZPHC 30 mg premixed pen.

Why Product Verification Matters

One of the most important considerations when researching an investigational product is authenticity. Lilly warns that products claiming to be retatrutide outside its clinical-trial system may contain unknown ingredients, contaminants, incorrect quantities of active ingredients, or entirely different substances.

That creates a potentially serious negative issue for consumers: a product’s label, website description, or packaging cannot independently confirm its identity or quality.

Consumers researching ZPHC or retatrutide should therefore consider:

• Whether the product has FDA approval.
• Whether the stated manufacturer can be independently verified.
• Whether the product is being supplied through an authorized clinical-trial pathway.
• Whether claims about safety or effectiveness are supported by appropriate evidence.
• Whether the labeling accurately identifies the active compound.
• Whether the product’s storage and handling requirements are documented.
• Whether a qualified healthcare professional can provide appropriate guidance.

Research Interest and Future Development

The scientific interest surrounding retatrutide continues to grow as additional Phase 3 data become available. Lilly is studying the molecule across several clinical programs and has reported results involving obesity, type 2 diabetes, cardiovascular disease, osteoarthritis, and sleep apnea.

Lilly announced in July 2026 that it planned to submit a Biologics License Application for retatrutide to the FDA in the first quarter of 2027.

Until regulatory review and approval occur, however, retatrutide should continue to be regarded as an investigational compound rather than an approved treatment.

Reta ZPHC 30 mg Premixed Pen: Key Information

Product name: Reta ZPHC (AQ Pen)
Stated quantity: 30 mg
Format: Premixed pen
Compound referenced: Retatrutide
Regulatory status: Investigational; not FDA-approved as of September 2026
Research category: GIP/GLP-1/glucagon triple receptor agonist
Primary research areas: Obesity and metabolic health, among other investigational indications

The stated 30 mg quantity should not be interpreted as an approved therapeutic dose or as a recommendation for personal use. Clinical research protocols use defined dosing schedules and medical monitoring, and those protocols should not be replicated independently.

Frequently Asked Questions

Is Reta ZPHC FDA approved?

No. Retatrutide is not currently FDA-approved. It remains an investigational molecule in clinical development.

What is retatrutide?

Retatrutide is an investigational triple receptor agonist that activates GIP, GLP-1, and glucagon receptors.

Is a 30 mg premixed pen the same as an approved retatrutide medication?

No approved retatrutide medication currently exists. A product’s stated concentration, packaging, or pen format does not establish FDA approval or pharmaceutical equivalence.

Can consumers legally purchase retatrutide for personal use?

Lilly states that retatrutide is legally available only through its clinical trials and that it has not been approved by any regulatory agency.

Why is retatrutide attracting attention?

Interest has increased because Phase 3 clinical research has reported substantial effects on body weight and glycemic measures. Those findings remain part of an ongoing investigational program.

Final Considerations

Reta ZPHC (AQ Pen) — 30 mg Premixed Pen is a product listing associated with the investigational compound retatrutide. The compound has generated considerable scientific interest because of its triple GIP/GLP-1/glucagon mechanism and encouraging clinical-trial findings.

At the same time, the regulatory distinction is crucial. Retatrutide has not received FDA approval, and products claiming to contain retatrutide outside authorized clinical research cannot be assumed to have the identity, purity, potency, or safety demonstrated by clinical-trial materials.

For U.S. readers researching ZPHC, the most reliable approach is to verify current regulatory information, consult qualified healthcare professionals for medical questions, and rely on authorized clinical-trial or regulatory sources when evaluating investigational compounds.